Loading clinical trials...
Loading clinical trials...
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
Conditions
Interventions
MGD007
Locations
8
United States
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
H. Lee Moffitt Cancer Center & Research Institute, Inc
Tampa, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Duke University Medical Center
Durham, North Carolina, United States
Start Date
October 1, 2014
Primary Completion Date
July 2, 2018
Completion Date
July 2, 2018
Last Updated
February 8, 2022
NCT04704661
NCT06349642
NCT04511039
NCT04851119
NCT07281716
NCT07224724
Lead Sponsor
MacroGenics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions